File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases

TitleThe immune dysregulations in COVID-19: Implications for the management of rheumatic diseases
Authors
KeywordsCOVID-19
immune dysregulation
management
rheumatic diseases
Issue Date2021
PublisherSpringer Japan. The Journal's web site is located at http://link.springer.de/link/service/journals/10165/index.htm
Citation
Modern Rheumatology, 2021, v. 31 n. 5, p. 927-932 How to Cite?
AbstractThe pandemic of COVID-19 has caused global social impact and high health risk. Clinical observations have suggested that elevated levels of inflammatory mediators are associated with disease severities in COVID-19 patients, in which the immunological profiles indicate the hyperactivation of innate immune cells and dysregulated adaptive immune responses. The increasing prevalence and disease progression of COVID-19 has emerged as a pressing challenge for the management of rheumatic patients with immune dysregulations. Here we review the immune dysregulations in COVID-19 and discuss the management of COVID-19 patients with rheumatic diseases.
Persistent Identifierhttp://hdl.handle.net/10722/305084
ISSN
2023 Impact Factor: 1.8
2023 SCImago Journal Rankings: 0.727
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorXiao, F-
dc.contributor.authorHan, M-
dc.contributor.authorZhu, X-
dc.contributor.authorTang, Y-
dc.contributor.authorHuang, E-
dc.contributor.authorZou, H-
dc.contributor.authorJiang, Q-
dc.contributor.authorLu, L-
dc.date.accessioned2021-10-05T02:39:30Z-
dc.date.available2021-10-05T02:39:30Z-
dc.date.issued2021-
dc.identifier.citationModern Rheumatology, 2021, v. 31 n. 5, p. 927-932-
dc.identifier.issn1439-7595-
dc.identifier.urihttp://hdl.handle.net/10722/305084-
dc.description.abstractThe pandemic of COVID-19 has caused global social impact and high health risk. Clinical observations have suggested that elevated levels of inflammatory mediators are associated with disease severities in COVID-19 patients, in which the immunological profiles indicate the hyperactivation of innate immune cells and dysregulated adaptive immune responses. The increasing prevalence and disease progression of COVID-19 has emerged as a pressing challenge for the management of rheumatic patients with immune dysregulations. Here we review the immune dysregulations in COVID-19 and discuss the management of COVID-19 patients with rheumatic diseases.-
dc.languageeng-
dc.publisherSpringer Japan. The Journal's web site is located at http://link.springer.de/link/service/journals/10165/index.htm-
dc.relation.ispartofModern Rheumatology-
dc.rightsThis version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/[insert DOI]-
dc.subjectCOVID-19-
dc.subjectimmune dysregulation-
dc.subjectmanagement-
dc.subjectrheumatic diseases-
dc.titleThe immune dysregulations in COVID-19: Implications for the management of rheumatic diseases-
dc.typeArticle-
dc.identifier.emailXiao, F: xiaof@hku.hk-
dc.identifier.emailHuang, E: heyhk49@hku.hk-
dc.identifier.emailLu, L: liweilu@hku.hk-
dc.identifier.authorityLu, L=rp00477-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1080/14397595.2020.1868673-
dc.identifier.pmid33427554-
dc.identifier.pmcidPMC7852258-
dc.identifier.scopuseid_2-s2.0-85099812607-
dc.identifier.hkuros326294-
dc.identifier.volume31-
dc.identifier.issue5-
dc.identifier.spage927-
dc.identifier.epage932-
dc.identifier.isiWOS:000611636200001-
dc.publisher.placeJapan-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats